Skip to content

Study · Systematic review · n = 28,827 · 2025

5 results

Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.

Wen J, Syed B, Nadora D, How-Volkman C, Bernstein E, Truong A, Akhtar M, Razick A, Puglisi J, Frezza E

Endocrinology, diabetes & metabolism1 May 2025Cited by 13 (Europe PMC)

PMID40184508 (opens in a new tab)PMCIDPMC11970626 (opens in a new tab)DOI10.1002/edm2.70045 (opens in a new tab)PepBankPUB-40184508
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

IntroductionGlucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as an efficacious treatment for type 2 diabetes mellitus (T2DM) and have demonstrated substantial weight loss effects. This systematic review compares two prevalent GLP-1RAs, tirzepatide and semaglutide, with their weight loss effects and rates of adverse events (AEs).MethodsFollowing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), a systematic search was performed in PubMed, Embase and Cochrane Library for direct comparative studies between tirzepatide and semaglutide. A meta-analysis was conducted via a random-effects model to analyse the differences in weight loss outcomes between study cohorts.ResultsFour studies, with 28,827 patients (14,870 tirzepatide/13,928 semaglutide), mean age of 55.7 years (52.0 to 63.7) and mean follow-up of 35.9 weeks (23.6 to 44.6), were included in this study. Mean weight change across four studies for tirzepatide and semaglutide was -11.4% (-15.3% to -8.27%) and -7.3% (-8.3% to -6.08%), respectively. The meta-analysis supports these findings with a mean difference of -4.84 kg (95% CI: -6.21 to -3.47), favouring tirzepatide. The most common AEs were minor and moderate-severity gastrointestinal (GI) AEs.ConclusionCurrent literature supports tirzepatide demonstrating a higher impact on weight loss than semaglutide, with both demonstrating high rates of minimal- to moderate-severity AEs. Further research with comparative head-to-head trials will better elucidate these weight loss effects and safety profiles.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a meta-analysis found a mean weight difference of -4.84 kg favouring tirzepatide over semaglutide.

    In plain wordsIn adults with type 2 diabetes, tirzepatide led to more weight loss than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight difference, tirzepatide versus semaglutide
    Study

    n = 28,827

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference in weight
    −4.84 kg
    tirzepatide vs semaglutide

    Source sentences

    Summary
    The meta-analysis supports these findings with a mean difference of -4.84 kg (95% CI: -6.21 to -3.47), favouring tirzepatide.
    2 context sentences
    Summary · context
    Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), a systematic search was performed in PubMed, Embase and Cochrane Library for direct comparative studies between tirzepatide and semaglutide.
    Summary · context
    Four studies, with 28,827 patients (14,870 tirzepatide/13,928 semaglutide), mean age of 55.7 years (52.0 to 63.7) and mean follow-up of 35.9 weeks (23.6 to 44.6), were included in this study.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide was linked to a mean weight change of -11.4% across four studies.

    In plain wordsIn adults with type 2 diabetes, people on tirzepatide lost weight across four studies.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMean weight change across four studies
    Study

    n = 14,870

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean weight change
    −11.4%
    tirzepatide

    Source sentences

    Summary
    Mean weight change across four studies for tirzepatide and semaglutide was -11.4% (-15.3% to -8.27%) and -7.3% (-8.3% to -6.08%), respectively.
    2 context sentences
    Summary · context
    Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), a systematic search was performed in PubMed, Embase and Cochrane Library for direct comparative studies between tirzepatide and semaglutide.
    Summary · context
    Four studies, with 28,827 patients (14,870 tirzepatide/13,928 semaglutide), mean age of 55.7 years (52.0 to 63.7) and mean follow-up of 35.9 weeks (23.6 to 44.6), were included in this study.
  3. 03HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, the most common adverse events with tirzepatide were minor and moderate gastrointestinal events.

    In plain wordsIn adults with type 2 diabetes, the most common side effects of tirzepatide were mild to moderate stomach and gut problems.

    Peptide
    Tirzepatide
    Outcome
    Not applicableAdverse events (mostly gastrointestinal)
    Study

    n = 14,870

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The most common AEs were minor and moderate-severity gastrointestinal (GI) AEs.
    2 context sentences
    Summary · context
    Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), a systematic search was performed in PubMed, Embase and Cochrane Library for direct comparative studies between tirzepatide and semaglutide.
    Summary · context
    Four studies, with 28,827 patients (14,870 tirzepatide/13,928 semaglutide), mean age of 55.7 years (52.0 to 63.7) and mean follow-up of 35.9 weeks (23.6 to 44.6), were included in this study.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, semaglutide was linked to a mean weight change of -7.3% across four studies.

    In plain wordsIn adults with type 2 diabetes, people on semaglutide lost weight across four studies.

    Peptide
    Semaglutide
    Outcome
    DecreaseMean weight change across four studies
    Study

    n = 13,928

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean weight change
    −7.3%
    semaglutide

    Source sentences

    Summary
    Mean weight change across four studies for tirzepatide and semaglutide was -11.4% (-15.3% to -8.27%) and -7.3% (-8.3% to -6.08%), respectively.
    2 context sentences
    Summary · context
    Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), a systematic search was performed in PubMed, Embase and Cochrane Library for direct comparative studies between tirzepatide and semaglutide.
    Summary · context
    Four studies, with 28,827 patients (14,870 tirzepatide/13,928 semaglutide), mean age of 55.7 years (52.0 to 63.7) and mean follow-up of 35.9 weeks (23.6 to 44.6), were included in this study.
  5. 05HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, the most common adverse events with semaglutide were minor and moderate gastrointestinal events.

    In plain wordsIn adults with type 2 diabetes, the most common side effects of semaglutide were mild to moderate stomach and gut problems.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdverse events (mostly gastrointestinal)
    Study

    n = 13,928

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The most common AEs were minor and moderate-severity gastrointestinal (GI) AEs.
    2 context sentences
    Summary · context
    Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), a systematic search was performed in PubMed, Embase and Cochrane Library for direct comparative studies between tirzepatide and semaglutide.
    Summary · context
    Four studies, with 28,827 patients (14,870 tirzepatide/13,928 semaglutide), mean age of 55.7 years (52.0 to 63.7) and mean follow-up of 35.9 weeks (23.6 to 44.6), were included in this study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.